Insider transactions

EDGAR

LeonaBio, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
1 transactions, 3,149,470 shares
Sum of shares × price per share: 9,919,161,280.9
Open-market sales (code S)
10 transactions, 16,748 shares
Sum of shares × price per share: 99,418.05

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 74

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-26 Filed 2026-10-28Portman David J. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,149,4703,149.47
9,919,161,280.9

Derived: shares × price per share. Exact value 9919161280.90.

3,149,470Indirect (I) See noteNo— Open filing 0002126186-26-000002 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-28Portman David J. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Derivative security: Warrant — underlying Common Stock (5,502,402) — exercise price 0.001
Disposed (D)5,502,4023,149.47
17,329,650,026.94

Derived: shares × price per share. Exact value 17329650026.94.

0Indirect (I) See noteNo
F1, F2, F3
  • F1 The shares are held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. This Form 4 is being filed to report Dr. Portman's voting control over such securities, but Dr. Portman's personal indirect beneficial ownership does not exceed 10% of the stock in the Issuer.
  • F2 The Warrant does not expire.
  • F3 The Warrant was held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. The Warrant was exercised on October 26, 2026, in part, into 3,149,740 Common Shares of Issuer, and the balance of the Warrant was assigned to Perceptive Xentogeny Venture Fund II, LP as a distribution-in-kind pursuant to a plan of distribution to the Sermonix Pharmaceuticals equity holders. Following the partial exercise and the assignment of the remaining Warrant rights, Sermonix Pharmaceuticals holds 3,149,740 Common Shares of Issuer.
Open filing 0002126186-26-000002 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-26PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)776,6480.001
776.648

Derived: shares × price per share. Exact value 776.648.

776,648Indirect (I) See FootnotesNo
F1, F7
  • F1 The securities are directly held by Sermonix Pharmaceuticals, Inc. (Sermonix). An affiliate of Perceptive Advisors LLC (the Advisor) currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix.
  • F7 Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Open filing 0001193125-26-431896 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-26PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Pre-Funded Warrant (right to buy) — underlying Common Stock (776,648) — exercise price 0.001
Disposed (D)776,648——0Indirect (I) See FootnotesNo
F4, F5, F6, F1, F7
  • F4 The securities were issued to Sermonix in exchange for the grant of certain licenses and rights by Sermonix to the Issuer. The Pre-Funded Warrants became exercisable on March 18, 2026 upon receipt by the Issuer of stockholder approval such that the Pre-Funded Warrants can be exercised at any time without restriction or additional stockholder approval.
  • F5 The Pre-Funded Warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 49.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise.
  • F6 The Pre-Funded Warrants do not expire.
  • F1 The securities are directly held by Sermonix Pharmaceuticals, Inc. (Sermonix). An affiliate of Perceptive Advisors LLC (the Advisor) currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). Pursuant to General Instruction 4.b.(iv) of Form 4, the Reporting Persons with this filing have reported the entire amount of Sermonix's interest in the securities, rather than the Reporting Person's proportionate interest in the securities held by Sermonix.
  • F7 Each of Mr. Edelman, the Advisor, the Master Fund and PXV II disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Open filing 0001193125-26-431896 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-07-09PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Indirect (I) See footnoteNo
F1, F2
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
  • F2 Joseph Edelman (Mr. Edelman) is the managing member of Perceptive Advisors LLC (the Advisor). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the Master Fund). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Open filing 0001193125-26-299927 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Holles Natalie C. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,333) — exercise price 8.35
Acquired (A)2,3330—2,333Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.
Open filing 0001580111-26-000010 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24PICKERING GRANT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001258693-26-000011 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Silverman Peter B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,333) — exercise price 8.35
Acquired (A)2,3330—2,333Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.
Open filing 0001790314-26-000004 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Romano Kelly A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001722055-26-000005 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24EDELMAN JOSEPH Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001164426-26-000003 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Callori Fred Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,333) — exercise price 8.35
Acquired (A)2,3330—2,333Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.
Open filing 0001843393-26-000006 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Panzara Michael A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001679039-26-000003 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24JOHNSON JAMES A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001225501-26-000003 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-24Kosacz Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 8.35
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Open filing 0001763316-26-000004 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-07Callori Fred Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (56,000) — exercise price 9.63
Acquired (A)56,0000—56,000Direct (D) No
F1
  • F1 The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001843393-26-000004 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-07Holles Natalie C. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (56,000) — exercise price 9.63
Acquired (A)56,0000—56,000Direct (D) No
F1
  • F1 The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001580111-26-000007 Read from the filing’s XML Dispute this row
2026-05-05 Filed 2026-05-07Silverman Peter B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (56,000) — exercise price 9.63
Acquired (A)56,0000—56,000Direct (D) No
F1
  • F1 The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001790314-26-000003 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-07-10PERCEPTIVE ADVISORS LLC Director · 10% ownerEDELMAN JOSEPH Director · 10% ownerPERCEPTIVE LIFE SCIENCES MASTER FUND LTD Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Indirect (I) See footnoteNo
F1, F2
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
  • F2 Joseph Edelman (Mr. Edelman) is the managing member of Perceptive Advisors LLC (the Advisor). The Advisor serves as the investment manager of Perceptive Life Sciences Master Fund Ltd. (the Master Fund). The Advisor may be deemed to have an indirect pecuniary interest in the securities reported herein because the Advisor has the right to receive the director compensation provided in respect of Mr. Edelman's board service through a partial management fee offset. Each of the Master Fund and the Advisor disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that either the Master Fund or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Open filing 0001193125-26-300876 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13EDELMAN JOSEPH Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001164426-26-000002 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13FLUKE JOHN M JR Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001191906-26-000002 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Romano Kelly A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001722055-26-000004 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Panzara Michael A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001679039-26-000002 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Renninger Robert Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 9.54
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0002037968-26-000006 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Worthington Mark Officer: GENERAL COUNSEL and CCO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 9.54
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001861464-26-000006 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13San Martin Javier Officer: CHIEF MEDICAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (350,000) — exercise price 9.54
Acquired (A)350,0000—350,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001794629-26-000006 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13PICKERING GRANT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001258693-26-000008 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13JOHNSON JAMES A Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001225501-26-000002 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Kosacz Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (28,000) — exercise price 9.54
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001763316-26-000002 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13Litton Mark James Director · Officer: PRESIDENT and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (750,000) — exercise price 9.54
Acquired (A)750,0000—750,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001604834-26-000008 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 9.54
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.
Open filing 0001822499-26-000006 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Renninger Robert Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)9065.37
4,865.22

Derived: shares × price per share. Exact value 4865.22.

15,851Direct (D) No
F1, F2
  • F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.
  • F2 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Worthington Mark Officer: GENERAL COUNSEL and CCO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,3285.37
7,131.36

Derived: shares × price per share. Exact value 7131.36.

18,376Direct (D) No
F1, F2
  • F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.
  • F2 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,3595.37
7,297.83

Derived: shares × price per share. Exact value 7297.83.

25,178Direct (D) No
F1, F2
  • F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.
  • F2 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05San Martin Javier Officer: CHIEF MEDICAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,7205.37
9,236.4

Derived: shares × price per share. Exact value 9236.40.

15,887Direct (D) No
F1, F2
  • F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.
  • F2 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row
2026-03-04 Filed 2026-03-05Litton Mark James Director · Officer: PRESIDENT and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)5,1565.37
27,687.72

Derived: shares × price per share. Exact value 27687.72.

57,926Direct (D) No
F1, F2
  • F1 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person.
  • F2 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Renninger Robert Officer: CHIEF FINANCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,9000—16,757Direct (D) No— Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Renninger Robert Officer: CHIEF FINANCIAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (3,900)
Disposed (D)3,9000—0Direct (D) No
F3, F4
  • F3 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  • F4 On March 3, 2025, the reporting person was granted 3,900 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
Open filing 0002037968-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Worthington Mark Officer: GENERAL COUNSEL and CCO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,7260—19,704Direct (D) No— Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Worthington Mark Officer: GENERAL COUNSEL and CCO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,726)
Disposed (D)5,7260—0Direct (D) No
F3, F4
  • F3 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  • F4 On March 3, 2025, the reporting person was granted 5,726 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
Open filing 0001861464-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)5,8560—26,537Direct (D) No— Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (5,856)
Disposed (D)5,8560—0Direct (D) No
F3, F4
  • F3 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  • F4 On March 3, 2025, the reporting person was granted 5,856 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
Open filing 0001822499-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05San Martin Javier Officer: CHIEF MEDICAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,4180—17,607Direct (D) No— Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05San Martin Javier Officer: CHIEF MEDICAL OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (7,418)
Disposed (D)7,4180—0Direct (D) No
F3, F4
  • F3 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  • F4 On March 3, 2025, the reporting person was granted 7,418 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
Open filing 0001794629-26-000004 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Litton Mark James Director · Officer: PRESIDENT and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)22,2540—63,082Direct (D) No— Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-05Litton Mark James Director · Officer: PRESIDENT and CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (22,254)
Disposed (D)22,2540—0Direct (D) No
F6, F7
  • F6 Each RSU represents a contingent right to receive one (1) share of Issuer's common stock.
  • F7 On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
Open filing 0001604834-26-000006 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05San Martin Javier Officer: CHIEF MEDICAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,6446.88
11,310.72

Derived: shares × price per share. Exact value 11310.72.

10,189Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald amp; Co. entered into in connection with the Issuer's private placement in December 2025.
  • F3 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001794629-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Renninger Robert Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2976.88
2,043.36

Derived: shares × price per share. Exact value 2043.36.

12,857Direct (D) No
F5, F6
  • F5 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald amp; Co. entered into in connection with the Issuer's private placement in December 2025.
  • F6 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0002037968-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Litton Mark James Director · Officer: President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,5866.88
17,791.68

Derived: shares × price per share. Exact value 17791.68.

40,828Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald amp; Co. entered into in connection with the Issuer's private placement in December 2025.
  • F3 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001604834-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05Worthington Mark Officer: General Counsel and CCO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8766.88
6,026.88

Derived: shares × price per share. Exact value 6026.88.

13,978Direct (D) No
F2, F3
  • F2 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of Common Stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald Co. entered into in connection with the Issuer's private placement in December 2025.
  • F3 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001861464-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-05CHURCH KEVIN Officer: CHIEF SCIENTIFIC OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)8766.88
6,026.88

Derived: shares × price per share. Exact value 6026.88.

20,681Direct (D) No
F5, F6
  • F5 Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units (RSU) pursuant to mandatory sell to cover policies maintained by the issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person and the shares of common stock received upon settlement of the RSUs are subject to a lock-up agreement with Cantor Fitzgerald amp; Co. entered into in connection with the Issuer's private placement in December 2025.
  • F6 The Amount and Price reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $6.60 to $7.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Open filing 0001822499-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–49 of 49

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
PERCEPTIVE ADVISORS LLC 1,859,322 SH6,637,779 dollarsUnchanged Prior quarter: 1,859,322Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
ACORN CAPITAL ADVISORS, LLC 1,144,416 SH4,085,565 dollarsHigher by 509,877 Prior quarter: 634,539Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 777,100 SH2,774,247 dollarsUnchanged Prior quarter: 777,100Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 467,886 SH1,670,353 dollarsHigher by 167,886 Prior quarter: 300,000Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
TCG Crossover Management, LLC 464,398 SH1,657,901 dollarsUnchanged Prior quarter: 464,398Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row
Commodore Capital LP 464,398 SH1,657,901 dollarsUnchanged Prior quarter: 464,398Open filing 0001831942-26-000052 Filed 2026-11-16 Dispute this row
NEA Management Company, LLC 464,398 SH1,657,901 dollarsUnchanged Prior quarter: 464,398Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row
Spruce Street Capital LP 393,701 SH1,405,513 dollarsUnchanged Prior quarter: 393,701Open filing 0002050194-26-000006 Filed 2026-11-13 Dispute this row
Kalehua Capital Management LLC 393,701 SH1,405,513 dollarsLower by 393,701 Prior quarter: 787,402Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 275,233 SH982,582 dollarsUnchanged Prior quarter: 275,233Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Seven Fleet Capital Management LP 158,253 SH564,963 dollarsHigher by 4,100 Prior quarter: 154,153Open filing 0001013594-26-001198 Filed 2026-11-16 Dispute this row
Simplify Asset Management Inc. 149,279 SH532,926 dollarsUnchanged Prior quarter: 149,279Open filing 0001172661-26-004722 Filed 2026-10-27 Dispute this row
Propel Bio Management, LLC Partly reported under another manager149,279 SH532,926 dollarsUnchanged Prior quarter: 149,279Open filing 0001829126-26-012373 Filed 2026-11-13 Dispute this row
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. Partly reported under another manager99,109 SH353,819 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-007537 Filed 2026-11-10 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager86,282 SH308,027 dollarsHigher by 76,281 Prior quarter: 10,001Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager85,336 SH304,835 dollarsHigher by 4,918 Prior quarter: 80,418Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
BlackRock, Inc. Partly reported under another manager78,059 SH278,671 dollarsLower by 1,127 Prior quarter: 79,186Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager56,966 SH203,369 dollarsLower by 20,458 Prior quarter: 77,424Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
LUMINUS MANAGEMENT LLC 47,656 SH170,132 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128425 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 42,814 SH152,846 dollarsUnchanged Prior quarter: 42,814Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Nantahala Capital Management, LLC 37,661 SH134,450 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager32,555 SH116,221 dollarsLower by 2 Prior quarter: 32,557Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 28,620 SH102,173 dollarsLower by 3,830 Prior quarter: 32,450Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager19,381 SH69,190 dollarsHigher by 4,653 Prior quarter: 14,728Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager18,027 SH64,357 dollarsNot in the prior quarter’s filings read Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager16,337 SH58,323 dollarsUnchanged Prior quarter: 16,337Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager14,394 SH51,387 dollarsUnchanged Prior quarter: 14,394Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
TWO SIGMA INVESTMENTS, LP 13,276 SH47,395 dollarsUnchanged Prior quarter: 13,276Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager10,357 SH36,974 dollarsLower by 1,392 Prior quarter: 11,749Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager10,230 SH36 dollarsUnchanged Prior quarter: 10,230Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
Laird Norton Wetherby Trust Company, LLC 10,088 SH36,014 dollarsLower by 11,730 Prior quarter: 21,818Open filing 0001172661-26-005286 Filed 2026-11-16 Dispute this row
SCOGGIN MANAGEMENT LP Partly reported under another manager10,000 SH35,700 dollarsNot in the prior quarter’s filings read Open filing 0002060757-26-000061 Filed 2026-11-16 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager2,200 SH7,721 dollarsLower by 2,380 Prior quarter: 4,580Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager2,012 SH7,062 dollarsUnchanged Prior quarter: 2,012Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Vanguard Global Advisers, LLC 1,325 SH4,730 dollarsUnchanged Prior quarter: 1,325Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager747 SH2,667 dollarsHigher by 309 Prior quarter: 438Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager578 SH2,063 dollarsHigher by 489 Prior quarter: 89Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager250 SH1,000 dollarsLower by 594 Prior quarter: 844Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
American Capital Advisory, LLC 200 SH714 dollarsUnchanged Prior quarter: 200Open filing 0002018007-26-000004 Filed 2026-10-28 Dispute this row
ROTHSCHILD INVESTMENT LLC 150 SH536 dollarsUnchanged Prior quarter: 150Open filing 0001104659-26-124996 Filed 2026-11-10 Dispute this row
McIlrath Eck, LLC 82 SH293 dollarsUnchanged Prior quarter: 82Open filing 0001701714-26-000005 Filed 2026-11-17 Dispute this row
US BANCORP \DE\ Partly reported under another manager81 SH289 dollarsUnchanged Prior quarter: 81Open filing 0000036104-26-000059 Filed 2026-11-05 Dispute this row
UBS Group AG Partly reported under another manager75 SH268 dollarsLower by 121 Prior quarter: 196Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Global Retirement Partners, LLC 52 SH185 dollarsUnchanged Prior quarter: 52Open filing 0001580642-26-007620 Filed 2026-11-10 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager33 SH107 dollarsUnchanged Prior quarter: 33Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager20 SH71 dollarsUnchanged Prior quarter: 20Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
SBI Securities Co., Ltd. 12 SH43 dollarsUnchanged Prior quarter: 12Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
BARCLAYS PLC Partly reported under another manager2 SH7 dollarsLower by 40 Prior quarter: 42Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Caitong International Asset Management Co., Ltd 1 SH4 dollarsLower by 5 Prior quarter: 6Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Blackstone Inc. 324,638 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Great Point Partners, LLC Common Stock, $0.0001 par value per share5.03474,345.0010/28/2026 Filed 2026-11-04SCHEDULE 13GOpen filing 0001172661-26-004856 Dispute this row
Dr. Jeffrey R. Jay, M.D. Common Stock, $0.0001 par value per share5.03474,345.0010/28/2026 Filed 2026-11-04SCHEDULE 13GOpen filing 0001172661-26-004856 Dispute this row
Ms. Lillian Nordahl Common Stock, $0.0001 par value per share5.03474,345.0010/28/2026 Filed 2026-11-04SCHEDULE 13GOpen filing 0001172661-26-004856 Dispute this row
Sermonix Pharmaceuticals, Inc. Common Stock25.13,149,470.0010/26/2026 Filed 2026-10-28SCHEDULE 13D/AAmendment 1Open filing 0001655566-26-000004 Dispute this row
Portman David J. Common Stock25.13,149,470.0010/26/2026 Filed 2026-10-28SCHEDULE 13D/AAmendment 1Open filing 0001655566-26-000004 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value19.991,889,40310/26/2026 Filed 2026-10-26SCHEDULE 13D/AAmendment 9Open filing 0001193125-26-431897 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value19.991,889,40310/26/2026 Filed 2026-10-26SCHEDULE 13D/AAmendment 9Open filing 0001193125-26-431897 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value16.51,559,64710/26/2026 Filed 2026-10-26SCHEDULE 13D/AAmendment 9Open filing 0001193125-26-431897 Dispute this row
Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value3.8359,83710/26/2026 Filed 2026-10-26SCHEDULE 13D/AAmendment 9Open filing 0001193125-26-431897 Dispute this row
Spruce Street Capital LP Common Stock, par value $0.0001 per share4.2393,700.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0000902664-26-004525 Dispute this row
Alex R. Rosen Common Stock, par value $0.0001 per share4.2393,700.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0000902664-26-004525 Dispute this row
Simon Basseyn Common Stock, par value $0.0001 per share4.2393,700.0009/30/2026 Filed 2026-11-13SCHEDULE 13GOpen filing 0000902664-26-004525 Dispute this row
Sermonix Pharmaceuticals, Inc. Common Stock36.95,502,402.0008/24/2026 Filed 2026-08-31SCHEDULE 13DOpen filing 0001655566-26-000003 Dispute this row
Portman David J. Common Stock36.95,502,402.0008/24/2026 Filed 2026-08-31SCHEDULE 13DOpen filing 0001655566-26-000003 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value19.991,889,40308/22/2026 Filed 2026-08-25SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-365096 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value19.991,889,40308/22/2026 Filed 2026-08-25SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-365096 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value16.51,559,64708/22/2026 Filed 2026-08-25SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-365096 Dispute this row
Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value3.8359,83708/22/2026 Filed 2026-08-25SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-365096 Dispute this row
ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value5.1480,653.0008/18/2026 Filed 2026-08-20SCHEDULE 13G/AAmendment 2Open filing 0001636587-26-000069 Dispute this row
ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value5.1480,653.0008/18/2026 Filed 2026-08-20SCHEDULE 13G/AAmendment 2Open filing 0001636587-26-000069 Dispute this row
ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value7.0663,763.0008/18/2026 Filed 2026-08-20SCHEDULE 13G/AAmendment 2Open filing 0001636587-26-000069 Dispute this row
Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value7.0663,763.0008/18/2026 Filed 2026-08-20SCHEDULE 13G/AAmendment 2Open filing 0001636587-26-000069 Dispute this row
Anders Hove Common Stock, $0.0001 Par Value12.11,492,521.0008/18/2026 Filed 2026-08-20SCHEDULE 13G/AAmendment 2Open filing 0001636587-26-000069 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value19.991,882,37005/05/2026 Filed 2026-05-07SCHEDULE 13D/AAmendment 7Open filing 0001193125-26-212047 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value19.991,882,37005/05/2026 Filed 2026-05-07SCHEDULE 13D/AAmendment 7Open filing 0001193125-26-212047 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value16.51,552,61405/05/2026 Filed 2026-05-07SCHEDULE 13D/AAmendment 7Open filing 0001193125-26-212047 Dispute this row
Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value3.7352,80405/05/2026 Filed 2026-05-07SCHEDULE 13D/AAmendment 7Open filing 0001193125-26-212047 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.0001 par value per share7.7727,481.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001104659-26-062870 Dispute this row
Daniel Schneeberger Common Stock, $0.0001 par value per share7.7727,481.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0001104659-26-062870 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value19.991,859,32201/16/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 6Open filing 0001193125-26-015471 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value19.991,859,32201/16/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 6Open filing 0001193125-26-015471 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value16.41,529,56601/16/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 6Open filing 0001193125-26-015471 Dispute this row
Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value3.5329,75601/16/2026 Filed 2026-01-16SCHEDULE 13D/AAmendment 6Open filing 0001193125-26-015471 Dispute this row
ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value2.6250,348.0001/06/2026 Filed 2026-01-08SCHEDULE 13G/AAmendment 1Open filing 0001636587-26-000001 Dispute this row
ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value2.6250,348.0001/06/2026 Filed 2026-01-08SCHEDULE 13G/AAmendment 1Open filing 0001636587-26-000001 Dispute this row
ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value3.6345,720.0001/06/2026 Filed 2026-01-08SCHEDULE 13G/AAmendment 1Open filing 0001636587-26-000001 Dispute this row
Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value3.6345,720.0001/06/2026 Filed 2026-01-08SCHEDULE 13G/AAmendment 1Open filing 0001636587-26-000001 Dispute this row
Anders Hove Common Stock, $0.0001 Par Value6.2596,068.0001/06/2026 Filed 2026-01-08SCHEDULE 13G/AAmendment 1Open filing 0001636587-26-000001 Dispute this row
Baselake Partners, LP Common Stock, $0.0001 par value per share1.975,78912/31/2025 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000008 Dispute this row
Baselake Management, LLC Common Stock, $0.0001 par value per share1.975,78912/31/2025 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000008 Dispute this row
David Paolella Common Stock, $0.0001 par value per share1.975,78912/31/2025 Filed 2026-02-06SCHEDULE 13G/AAmendment 1Open filing 0001957912-26-000008 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value19.991,859,32212/23/2025 Filed 2025-12-23SCHEDULE 13D/AAmendment 5Open filing 0001193125-25-331145 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value20.11,869,05012/23/2025 Filed 2025-12-23SCHEDULE 13D/AAmendment 5Open filing 0001193125-25-331145 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value16.41,529,56612/23/2025 Filed 2025-12-23SCHEDULE 13D/AAmendment 5Open filing 0001193125-25-331145 Dispute this row
Perceptive Xontogeny Venture Fund II, LP Common Stock, $0.0001 par value3.5329,75612/23/2025 Filed 2025-12-23SCHEDULE 13D/AAmendment 5Open filing 0001193125-25-331145 Dispute this row
ACORN BIOVENTURES, L.P. Common Stock, $0.0001 Par Value2.2210,730.0012/22/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001636587-25-000065 Dispute this row
ACORN CAPITAL ADVISORS GP, LLC Common Stock, $0.0001 Par Value2.2210,730.0012/22/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001636587-25-000065 Dispute this row
ACORN BIOVENTURES 2, L.P. Common Stock, $0.0001 Par Value3.0291,009.0012/22/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001636587-25-000065 Dispute this row
Acorn Capital Advisors GP 2, LLC Common Stock, $0.0001 Par Value3.0291,009.0012/22/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001636587-25-000065 Dispute this row
Anders Hove Common Stock, $0.0001 Par Value5.2501,739.0012/22/2025 Filed 2025-12-23SCHEDULE 13GOpen filing 0001636587-25-000065 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015164,615
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to LeonaBio, Inc.